Determining a viral load threshold for pre-emptive therapy for cytomegalovirus infection in transplant patients using real time PCR monitoring.

Royal Free Hampstead NHS Trust0 个研究点目标入组 178 人开始时间: 2007年8月1日最近更新: 2019年12月10日

适应症

试验速览

暂无简介。

•1. All Stem Cell, Renal and Liver Transplant recipients
•2. Wiling to give informed consent
•3. A) All patients with CMV viraemia (between 200 and 3000 copies/ml) in the liver, renal and stem cell groups in two consecutive samples.
•B) Those patients requiring pre-emptive therapy because viral load is > 3,000 copies/ml
•4. All patients in either section of the study must be available for CMV PCR monitoring at least twice per week.
•Are the trial subjects under 18? yes
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Profound neutropaenia considered to preclude administration of ganciclovir or profound renal failure considered to preclude administration of foscarnet
•2. Inability to give informed consent
•3. In the stem cell group, Donor negative, Recipient negative transplants.
•4. In the stem cell group: matched unrelated donors who are CMV seronegative
•5. Those patients who have been in Group A cannot then enter the Group B part of the study.
•6. Those patients who have been in Group B cannot then enter the Group A part of the study.

发起方

Royal Free Hampstead NHS Trust